ABSTRACT Bacterial metabolism is necessary for adaptation to the host microenvironment. Flexible metabolic pathways allow uropathogenic Escherichia coli (UPEC) to harmlessly reside in the human intestinal tract and cause disease upon extraintestinal colonization. E. coli intestinal colonization requires carbohydrates as a carbon source, while UPEC extraintestinal colonization requires gluconeogenesis and the tricarboxylic acid cycle. UPEC containing disruptions in two irreversible glycolytic steps involving 6-carbon (6-phosphofructokinase; pfkA) and 3-carbon (pyruvate kinase; pykA) substrates have no fitness defect during urinary tract infection (UTI); however, both reactions are catalyzed by isozymes: 6-phosphofructokinases Pfk1 and Pfk2, encoded by pfkA and pfkB, and pyruvate kinases Pyk II and Pyk I, encoded by pykA and pykF. UPEC strains lacking one or both phosphofructokinase-encoding genes (pfkB and pfkA pfkB) and strains lacking one or both pyruvate kinase genes (pykF and pykA pykF) were investigated to determine their regulatory roles in carbon flow during glycolysis by examining their fitness during UTI and in vitro growth requirements. Loss of a single phosphofructokinase-encoding gene has no effect on fitness, while the pfkA pfkB double mutant outcompeted the parental strain in the bladder. A defect in bladder and kidney colonization was observed with loss of pykF, while loss of pykA resulted in a fitness advantage. The pykA pykF mutant was indistinguishable from wild-type in vivo, suggesting that the presence of Pyk II rather than the loss of Pyk I itself is responsible for the fitness defect in the pykF mutant. These findings suggest that E. coli suppresses latent enzymes to survive in the host urinary tract.
basic physiology required to respond to diverse host environments (1) . It is well known that E. coli behaves as a harmless commensal while residing in the human intestinal tract; however, incursion outside this niche by specific ExPEC pathotypes causes human morbidity and mortality as a consequence from invasive urinary tract infections (UTIs). For E. coli to colonize both the intestine and extraintestinal environments, we reason that physiology and metabolism are critical factors. Indeed, it has been reported that E. coli undergoes metabolic prioritization allowing colonization of the nutrient rich host intestine using fucose metabolism, glycolysis, and the Entner-Doudoroff (ED) pathway (2-4) while simultaneously colonizing the nutrient-deficient urinary tract by undergoing amino acid catabolism, gluconeogenesis, and the tricarboxylic acid (TCA) cycle (1, (4) (5) (6) . While study of pathogen-specific virulence determinants is crucial to understanding the mechanisms underlying bacterial infection, examination of core metabolic pathways among ExPEC pathotypes may be more efficacious for the future development of therapeutics aimed at restricting growth during bacterial infections within specific host microenvironments.
Metabolic flexibility and the differential use of carbon sources are essential for bacteria to successfully colonize while adapting to and competing for nutrient availability in diverse host microenvironments. Central carbon metabolism connects all the pathways in the cell by providing carbon skeletons for biosynthesis of macromolecular building blocks and conversely represents convergence points for the catabolism of macromolecules. These central pathways are glycolysis, gluconeogenesis, the ED pathway, the pentose phosphate pathway, and the TCA cycle ( Fig. 1) . While commensal E. coli require the ED pathway and glycolysis for intestinal colonization (2, 7) , UPEC require the TCA cycle and gluconeogenesis to catabolize short peptides and amino acids during infection of the urinary tract (1) . By using a proteomics approach in E. coli pyelonephritis strain CFT073, 56 proteins involved in the catabolism of pentose sugars and metabolism of sugar acids, gluconate, gluconolactone, sialic acid, and fructose, as well as two central metabolism enzymes, transaldolase (TalA) and triosephosphate isomerase (TpiA), were identified to be highly expressed in human urine compared to iron-limited LB medium (1) . To further investigate the impact of central metabolism during uropathogenic E. coli (UPEC) fitness, each central metabolism pathway was systematically disrupted and examined in a murine model of ascending UTI. Gluconeogenesis and the TCA cycle were found to be required for UPEC fitness in vivo (1) . Because urine is composed of a dilute mixture of amino acids and peptides (8) , it is not surprising that glycolysis, the pentose phosphate pathway and the ED pathway were dispensable during UPEC colonization of the urinary tract (1, 5) . Surprisingly, Proteus mirabilis strain HI4320, a bacteriuria isolate cultured from a patient during long-term urinary catheterization (9, 10) , requires different central metabolism requirements during UTI in comparison to UPEC despite occupying the same host niche (5) . Glycolysis, the pentose phosphate pathway, and the ED pathway are required for P. mirabilis fitness (5) while being dispensable during UPEC UTI (1) . The processes in which these bacteria are assimilating available nitrogen sources in the same host environment is one explanation for these strikingly different metabolic requirements for infection (5) . E. coli, unable to utilize and sense low nitrogen levels, activates the glutamine synthetase and glutamate oxo-glutarate aminotransferase system (GS/GOGAT), while ureasepositive P. mirabilis uses glutamate dehydrogenase (Gdh) in response to excess ammonia production from urease-mediated urea hydrolysis (5) . These findings suggest that physiological differences between pathogenic bacteria dictates the metabolic requirements needed to adapt to a seemingly identical host environment.
Because many of the glycolytic enzymes examined to date in UPEC during UTI also have catalytic roles in gluconeogenesis, additional mutants were constructed in two irreversible steps of glycolysis to definitively rule out this pathways' importance for UPEC infection (5) . Strains with disruptions in glycolytic steps involving 6-carbon (6-phosphofructokinase; pfkA) and 3-carbon (pyruvate kinase; pykA) substrates had no defect in vivo (5) further supporting that glycolysis is dispensable during experimental UTI (1). One drawback from that work is that both of these irreversible glycolytic reactions can be catalyzed by two isozymes that are required for the catabolism of glucose into pyruvate. Due to the possibility of the redundant glycolytic enzymes concealing effects from the mutation of only one of the two isozymes, we extensively examined the regulatory roles of each isozyme to definitively rule out the involvement of glycolysis in CFT073 during UTI.
The irreversible step involving phosphofructokinase is an important control point within the preparatory phase of the glycolytic pathway. Phosphofructokinase isozymes Pfk1, encoded by pfkA, and Pfk2, encoded by pfkB, phosphorylate the key allosteric effectors fructose-6-phosphate (F6P) and AMP. The second half of glycolysis, colloquially known as the "payoff phase," results in the production of carbon skeletons that enter the TCA cycle and final substrate level phosphorylation to produce ATP. The product, pyruvate, either is used in other pathways for macromolecule biosynthesis or is further oxidized in the TCA cycle. The transfer of the phosphoryl group of phosphoenolpyruvate to ADP to form pyruvate and ATP is the last step in the glycolytic pathway and is irreversible under physiological conditions (11, 12) . The last and irreversible step during this phase to generate pyruvate is catalyzed by two pyruvate kinase isozymes, Pyk I and Pyk II, which are activated by phosphoenolpyruvate (PEP). Pyruvate kinase I is encoded by pykF, while pyruvate kinase II is encoded by pykA. Although the two enzymes are differentially regulated at the level of transcription, they do coexist in a range of metabolic states (13) (14) (15) (16) (17) (18) (19) . To address the roles of these key regulatory glycolytic isozymes during colonization of the urinary tract, single and double mutants were constructed in parental strain CFT073 and examined during experimental UTI, as well as in in vitro experiments.
Previous work with Shigella and Salmonella, closely related to E. coli, assessed the roles of pfkA and pfkB in bacterial physiology (20, 21) . In Shigella flexneri, it was revealed that pfkA mutants were no longer able to invade epithelial cells due to reduced expression of invasion proteins IpaB and IpaC in the mutant strain (20) . The pfkA mutant also displayed an altered lipopolysaccharide structure, lower intracellular ATP levels, and decreased expression of virulence regulators virF and virB (20) . This study demonstrates the concept that metabolism, specifically glycolysis, can have effects on both virulence gene expression and bacterial physiology. In Salmonella enterica, pfkA was proven to be the dominant enzyme over pfkB, although they were functionally redundant during in vitro growth (21) . The pfkA pfkB mutant was unable to utilize glucose as a carbon source and had reduced colonization in the liver and spleen after 4 days of infection (21) . Therefore, the culmination of altered gene expression and physiology due to metabolic shifts may lead to defects in colonization and infection in that disease model.
The role of pykA and pykF in E. coli central carbohydrate metabolism has been previously assessed in vitro (17, 22) . It was determined that pykF encodes the major enzyme, representing 80% of total pyruvate kinase activity within the cell during growth (22) . In that study, growth in minimal medium with amino acids and glucose was not affected by the deletion of either enzyme; however, with the elimination of amino acids from the growth medium, the pykA pykF double mutant had significantly increased doubling time under anaerobic conditions (17) . Even with slower growth, all pykA, pykF, and pykA pykF mutants were able to reach a stationary-phase optical density (OD) similar to the wild type (17) . It was previously observed in another study that deletion of both pyk genes resulted in a lack of growth on glucose when grown anaerobically, suggesting that the absence of pyruvate kinase results in insufficient production of pyruvate to facilitate redox balance during fermentation because the addition of fumarate to the medium to stimulate anaerobic respiration rescued the growth of the pykA pykF double-mutant strain (23) . It is important to note that the phosphotransferase system (PTS) can also produce pyruvate from PEP during group translocation (17) . These in vitro mechanistic studies provide insight into the role of isozymes in pyruvate biosynthesis, but the effect of this altered metabolic state during UTI is currently not known.
In this study, we confirm that glycolysis is not a requirement for extraintestinal infection by UPEC CFT073; however, our findings support the notion that adaptation to carbon flow within a niche is crucial for survival. After assessing two irreversible steps in glycolysis during experimental UTI, we discovered that the phosphofructokinase isozymes are not required for colonization yet the presence of two isozymes of pyruvate kinase is important for flexible metabolism. A defect in colonization was observed during loss of pykF (Pyk I), suggesting its importance during infection, while the loss of pykA (Pyk II) resulted in a fitness advantage. However, when both genes were disrupted, E. coli CFT073 was able to survive in vivo, validating previous findings that glycolysis during UTI is dispensable. We propose that the presence of Pyk I suppresses the detrimental effects of Pyk II that are observed in a pykF-null background. These findings suggest that suppression of latent enzymes and flexible metabolism are important for E. coli adaptation to diverse host environments.
RESULTS
Redundant phosphofructokinases have disparate functional requirements in vitro and are dispensable in vivo. The irreversible conversion of fructose-6-phosphate (F6P) into fructose 1,6-bisphosphate is the key regulatory step in the preparatory phase of glycolysis and is catalyzed by phosphofructokinase (Pfk) (Fig. 2A) . This reaction is coupled with the cleavage of a phosphate group from ATP resulting in ADP. In E. coli two phosphofructokinase isozymes, Pfk1 and Pfk2, are encoded by pfkA and pfkB, respectively. Previously, we determined that phosphofructokinase Pfk1 in CFT073 was dispensable during experimental UTI (5) (Fig. 2B) . To further investigate the regulatory role of the ancillary enzyme, Pfk2, and rule out its ability to compensate the loss of pfkA in vivo, the fitness of CFT073 mutant strain pfkB was examined. Similar to the pkfA mutant, the loss of pkfB did not cause a fitness defect in either the bladder or kidneys during experimental UTI (Fig. 2C ). These findings indicate that mutant strains that possess only Pfk1 or Pfk2 are indistinguishable in direct competition during UTI. Deletion of both pfkA and pfkB in CFT073 resulted in a median 2-log fitness advantage in the mouse bladder during cochallenge with the wild-type strain (P Ͻ 0.05) (Fig. 2D) , indicating that both phosphofructokinase isozymes are dispensable in vivo. This may suggest that the presence and activity of these enzymes are energetically unfavorable, especially in the bladder, during infection.
To determine whether the convergent phosphofructokinases have different in vitro requirements, growth was examined in LB medium, defined medium containing glucose or glycerol as the sole carbon source, and human urine. Compared to wild-type CFT073, no growth defect was observed for the pfkA single mutant (5), the pfkB single mutant, or the pfkA pfkB double mutant after growth in LB medium (Fig. 3A) . The single mutant pfkA (5) and the pfkA pfkB double mutant were unable to grow in defined medium containing 0.2% glucose as the sole carbon source (Fig. 3B ). Unlike pfkA, the pfkB single mutant had no growth defect in defined medium containing 0.2% glucose, indicating that Pfk1 is required for metabolism of glucose, whereas Pfk2 is dispensable. These findings suggest that Pfk1 and Pfk2 are not functionally redundant for growth on glucose and that a pfkB mutation has no effect under these growth conditions. As expected, all phosphofructokinase mutants were able to grow in defined medium containing 0.2% glycerol (Fig. 3C ) since this 3-carbon molecule bypasses the step catalyzed by phosphofructokinase and may indeed be gluconeogenic. Both in vitro growth defects of the pfkA single mutant and the pfkA pfkB double mutant in defined medium containing 0.2% glucose were restored to the wild-type phenotype when complemented with pGEN-pfkA (see Fig. S1A in the supplemental material), again emphasizing the dominant role of Pfk1 during glycolysis (24) . Because urine is a physiologically relevant growth medium for UPEC, we examined the in vitro growth of the single and double pfk mutant strains in human urine. All of the phosphofructokinase mutants were able to grow in human urine suggesting that loss of Pfk activity has no effect on the ability to grow on the dilute mixture of amino acids and peptides found in human urine (Fig. 3D ). This result, taken together with growth in LB medium, is a compelling indication that fructose 6-P and glucose 6-P, which are essential metabolites for a number of cellular macromolecules, could be obtained from gluconeogenic substrates during colonization of the urinary tract.
The pyruvate kinase isozymes are functionally redundant in vitro, and Pyk I is required in the presence of Pyk II for E. coli fitness during UTI. The enzymatic activity of pyruvate kinase (Pyk) controls the irreversible and regulatory step within the oxidative phase of glycolysis (Fig. 4A ). This reaction is required for the generation of 3-carbon pyruvate, which is a key intermediate in the flow of carbon into the TCA cycle and gluconeogenesis while generating ATP (Fig. 4A) . In E. coli CFT073, two pyruvate kinase isozymes, Pyk I and Pyk II, are encoded by pykF and pykA, respectively. Pyruvate kinase Pyk II of CFT073 was previously reported to be dispensable during experimental UTI, with the loss of this enzyme resulting in a median 1-log fitness advantage in the bladder of mice (P Ͻ 0.05) (5) (Fig. 4B) . Interestingly, loss of Pyk I was found to cause a 10-fold fitness defect in the bladder and kidneys of mice during experimental UTI (P Ͻ 0.05) (Fig. 4C) , indicating that Pyk I and Pyk II have disparate roles during infection. These findings are not surprising since Pyk I has been shown to be responsible for 80% of pyruvate kinase activity in E. coli (22) . We hypothesize that in the absence of Pyk I, Pyk II produces a detrimental effect that would typically be suppressed by the presence of Pyk I. As such, loss of Pyk II ameliorates the fitness defect caused by the loss of Pyk I as observed in the pykA pykF double mutant (Fig. 4D) .
To determine the in vitro regulatory roles of the pyruvate kinase isozymes, growth was observed in LB medium, defined medium containing either glucose or glycerol as the sole source of carbon, and human urine. As expected, the single and double pyruvate kinase mutants were able to grow in LB medium (5) (Fig. 5A ). In addition, the loss of pyruvate kinase did not result in notable growth defects in defined medium containing 0.2% glucose (Fig. 5B) ; however, during culture in defined medium containing 0.2% glycerol, the pykA pykF double mutant displayed a lack of growth (Fig. 5C ). These results are not unexpected since pyruvate kinase activity is required for growth on non-PTS sugars. These findings suggest that Pyk II and Pyk I are functionally redundant in vitro. Complementation with pGEN-pykF in single mutant pykF mutant and the pykA pykF double mutant resulted in the restoration of the wild-type phenotype during in vitro growth in defined medium containing 0.2% glycerol as the sole carbon source (Fig. S1B) . We also assessed growth in human urine, which partially mimics the milieu encountered by UPEC during UTI. Strains lacking either Pyk I or Pyk II, or lacking both had no observable growth defect in human urine (Fig. 5D) . Finding that the Pyk-deficient strains can grow in LB medium and, more relevant, in human urine indicates that these bacteria can use amino acids as a carbon source similar to the wild type and suggests that the carbon skeletons being utilized for growth are entering the central pathways as acetyl coenzyme A (acetyl-CoA), oxaloacetate, or other TCA cycle intermediates and bypassing the requirement for the pyruvate kinase step.
Disruption of pyruvate kinase activity results in a hypermotile phenotype. Because phosphofructokinase (pfkA) in Shigella flexneri was found to be required for epithelial cell invasion (20) , we sought to determine whether similar effects on virulence traits could be observed for UPEC. To examine whether disruptions in glycolysis have an effect on motility, a panel of CFT073 glycolysis mutants were examined for their ability to swim in tryptone 0.25% soft agar. Mutation of the phosphofructokinase encoding genes had little effect on motility, and the swimming diameters were not significantly different from wild-type CFT073 (Fig. 6A and B) . Interestingly, disruption of pyruvate kinase pykF or the loss of both pyruvate kinase genes, pykA and pykF, resulted in hypermotile phenotypes with mean diameters of 78.9 and 68.3 mm, respectively (Fig.  6A) , and were statistically significant in comparison to the mean swimming diameter, 48.8 mm, of wild-type CFT073 (P ϭ 0.0004 and P ϭ 0.0236, respectively) (Fig. 6B) . Although the loss of pykA consistently resulted in an increased swimming diameter, this observation was not statistically significant compared to the swimming diameter of wild-type CFT073 (Fig. 6A and B) . We also investigated the motility of a CFT073 triosephosphate isomerase (tpiA) mutant previously found to have a fitness defect in vivo (1) . TpiA catalyzes the reversible isomerization between glyceraldehyde-3-phosphate (G3P) and dihydroxyacetone phosphate (DHAP) and functions in both glycolysis and gluconeogenesis (25) . Loss of tpiA results in a drastic decrease in motility with a mean swimming diameter of 9.0 mm, which is a statistically significant reduction in comparison to the swimming diameter of wild-type CFT073 (P Ͻ 0.0001) (Fig. 6A and B) . Previously, work from our lab reported that motility and flagellar gene expression in E. coli CFT073 is inversely related to the production of type 1 fimbriae (fim) (26, 27) . Expression of type 1 fimbriae is driven by a promoter located within an invertible element (IE) that is able to switch between on and off orientations. Constitutive expression of type 1 fimbriae has been shown to result in a significant decrease in motility and flagellar gene expression, although the loss of type 1 fimbriae does not result in increased motility (26) . Because of this complex interplay between type 1 fimbriae and flagellum-mediated motility, the orientation of the IE within the CFT073 glycolysis mutants was examined following static growth in LB medium to investigate the hypermotile and hypomotile phenotypes observed in the motility assay. We hypothesized that the drastically crippled motility of the tpiA mutant indicates production of type 1 fimbriae; however, the fim promoter in this strain was found to be positioned in the off orientation (Fig. 6C and Fig. S2A ). These findings suggest that other factors in the tpiA mutant are playing a role in the lack of motility, or perhaps the loss of type 1 fimbriae results in the expression of other fimbrial types, as has been previously reported in fim-null strains (26, 28, 29) . Orientation of the fim promoter was also in the off position in the double phosphofructokinase mutant (pfkA pfkB), which is only slightly less motile than wild-type CFT073 (Fig. 6) . These results are similar to previous findings of a CFT073 strain with the fim promoter mutated in the off orientation (fim L-OFF) that results in a slightly decreased motility diameter compared to wild-type CFT073 (26) . The fim promoter of glycolysis mutants-pfkA, pfkB, pykA, pykF, and pykA pykF-demonstrated a mixture of cells in the on and off orientations similar to what is observed for wild-type CFT073 populations (Fig. 6C and Fig. S2A ). These findings are additional evidence that other factors underlie the motility phenotypes rather than production of type 1 fimbriae since the pykF single mutant and pykA pykF double mutant both had significant hypermotile phenotypes compared to the swimming motility of the wild type (Fig. 6B) . In that regard, we found a weak relationship (R 2 ϭ 0.53) between motility and the percentage of the bacterial population with the fim promoter situated in the on orientation; notably, this weak correlation is the inverse of expected results based on previous literature (26, 27) (Fig. S2B) . Historically, expression of the fim operon is generally off when motility, or fliC, is expressed. To better understand the expression of type 1 fimbriae under more physiologically relevant conditions, we also examined the orientation of the IE within the glycolysis mutants after static in vitro growth in human urine, which is a reasonable approximation for the growth environment encountered by UPEC in the urinary tract. Under these conditions, the type 1 fim promoter in all of the pfk and pyk mutant strains was positioned in the off orientation (data not shown). Taken together, the lack of relationship between fim expression and motility phenotypes in the glycolysis mutants suggests that the effect of disrupting glycolysis on motility may be entirely posttranscriptional and, as will be discussed, may be related more to the link between glycolysis and cellular respiration and the physiology of the cell, such as ATP levels or a reduction or increase in the proton gradient that drives flagellar rotation and motility.
To determine whether the observed motility phenotypes for the glycolysis mutants can be explained by changes in transcription, we utilized quantitative PCR (qPCR) to quantify the levels of flagella and fimbrial gene expression. We examined levels of the RNA polymerase sigma factor for the flagellar operon (fliA), flagellin (fliC), the type one fimbria major subunit (fimA), and pyelonephritis-associated pilus major subunits (papA and papA2). Although there were no statistically significant changes in gene expression in the glycolysis mutants compared to wild-type CFT073, we did observe a Ͼ2-fold downregulation of fliA and fliC in the tpiA mutant (Fig. S3) . The expression of the flagellar and fimbrial genes was also examined in E. coli CFT073 strains fim L-ON and fim L-OFF, and the results are included as controls. As expected, the expression of fimA was downregulated Ͼ2-fold in the fim L-OFF strain and upregulated in the fim L-ON strain in which the type 1 fimbrial promoter is oriented in the locked-off and locked-on positions, respectively. Interestingly, the results from the qPCR analysis do not correlate well with the previously observed motility phenotypes of the glycolysis mutants except for tpiA (Fig. 6A and B) . Hypermotile glycolysis pykF and pykA pykF mutants did not demonstrate increased fliC expression, while only pykA pykF mutants demonstrated a modest increase in fliA expression. Only the tpiA mutant showed both a reduced motility phenotype and decreased fliC and fliA expression (Fig. 6A and Fig. S3 ). These data, in combination with the invertible element data, suggest that the relationship between glycolysis and motility could be explained by the physiological state of the cell independent from the levels of flagellar gene expression or the quantity of FliC produced by the bacteria.
DISCUSSION
To successfully grow during host colonization and infection, pathogens have adapted their metabolism to replicate in specific host microenvironments. Studies of E. coli intestinal colonization have revealed that adaptive factors, such as the ability to use a broad range of sugars as a carbon source, provide a fitness advantage in the intestine (2, 7, 30, 31) . Our recent studies on E. coli metabolism during extraintestinal colonization found a requirement for gluconeogenesis and the TCA cycle during UTI (1, 5). Those studies supported the notion that E. coli use the dilute mixture of amino acids and peptides in urine as a carbon source during UTI. Thus, we hypothesized that central pathways required to catabolize sugars are dispensable for E. coli to colonize the urinary tract. In the present study, we sought to further test the hypothesis that glycolysis is dispensable during UTI due to weaknesses in our previous studies. Our previous work relied on mutant strains that lacked glycolytic steps that are not limited to glycolysis. For example, triose phosphate isomerase is reversible and has a gluconeogenic role, and the irreversible regulatory steps we studied previously also have multiple enzymes capable of performing the same reaction, specifically, Pfk1, Pfk2, Pyk I, and Pyk II.
Here, we report that the independent loss of either Pfk isozyme, responsible for catalyzing the irreversible conversion of F6P into fructose 1,6-bisphosphate, has no effect on E. coli CFT073 colonization during experimental UTI. Interestingly, the absence of both Pfk1 and Pfk2 provides UPEC with a fitness advantage during UTI, suggesting that the presence of both or even a single Pfk enzyme may in fact limit growth during colonization of the urinary tract. In pathogens with different lifestyles, such as the intracellular pathogen Shigella flexneri, the loss of pfkA in results in the inability to invade epithelial cells, suggesting that Pfk1 is important for membrane splashing and entry (20) . Interestingly, disruption of both Pfk isozymes in Salmonella enterica resulted in a colonization defect in the liver and spleen in a mouse model of typhoid fever (21) . Since high levels of ATP and low PEP inhibit the enzymatic activity of both phosphofructokinases, it seems likely that UPEC are growing rapidly on amino acids and peptides, rendering the presence of Pfk dispensable. This is consistent with our findings that gluconeogenesis is essential for UPEC fitness during UTI (1). Since Pfk mutant bacteria can use amino acids as a carbon source similar to the wild type, these findings suggest that the carbon skeletons being utilized for growth are entering the central pathways as pyruvate, acetyl-CoA, oxaloacetate, or other TCA cycle intermediates and can thus be used via gluconeogenesis that does not require Pfk activity to generate fructose 6-P and glucose 6-P, which are essential macromolecular building blocks for the cell. In vitro results with UPEC show that mutant strains lacking pfkA or both pfkA and pfkB behave as expected and were unable to grow on glucose, while loss of pfkB had no effect on growth with glucose as the carbon source. These findings are consistent with what is well known for E. coli; phosphofructokinase activity is largely driven by Pfk1 while only 5 to 10% of phosphofructokinase activity results from Pfk2 (24) . Unlike Pfk1, Pfk2 is weakly regulated by glycolytic intermediates, is inhibited by magnesium-ATP, and is genetically composed of rare codons with a weaker consensus promoter than pfkA (32) (33) (34) (35) .
On the opposite end of the glycolytic pathway, pyruvate kinase, Pyk, is the key allosteric event controlling the direction of carbon flow through the TCA cycle, catalyzing one substrate level phosphorylation (of two in glycolysis) to produce ATP and pyruvate. Pyruvate can be used in macromolecular biosynthesis or can be further oxidized in the TCA cycle. Of the two isozymes, Pyk I is responsible for the majority of pyruvate kinase activity (22) . Pyk I is activated by fructose 1,6-bisphosphate and is inhibited by ATP (11), while Pyk II is activated by several sugar phosphates and AMP (15, 36) and is positively regulated by the transcriptional regulator FNR (37) . Interestingly, the pyruvate kinase isozymes have divergent fitness requirements during CFT073 infection. Loss of pykF that encodes Pyk I resulted in reduced fitness in both bladder and kidneys, while loss of pykA that encodes Pyk II resulted in a fitness advantage, suggesting that Pyk II hinders the growth of UPEC during UTI. In support of this, when both Pyk are lost in the pykA pykF double mutant strain, fitness during UTI was restored to wild-type levels. These findings suggest that the presence of Pyk II rather than the loss of Pyk I itself is responsible for the fitness defect in the pykF mutant. The Pyk mutant bacteria grow as expected in vitro. None of the Pyk single or double mutant strains have a growth defect in LB medium, human urine, or in defined medium with glucose as the carbon source. Only strains lacking both Pyk I and Pyk II have a growth defect when cultured in defined medium with glycerol as a carbon source, and the growth can be restored by complementation with pykF.
For UPEC and the closely related avian pathogenic E. coli, it has been suggested that FNR regulates virulence factors such as motility and type 1 fimbriae (38, 39) . To better understand whether glycolysis might have a similar effect on the production of virulence traits in UPEC, we examined motility and fimbrial expression. We found that absence of one or both Pfk enzymes had no effect on motility in soft agar and had a limited or no effect on transcription of fliA or fliC. In contrast, strains lacking Pyk I had a hypermotile phenotype. In addition, we were unable to correlate the motility phenotype with expression of type 1 fimbriae, which have a reciprocal effect on motility (26, 27) . The only finding that is consistent is that loss of both Pfk enzymes does not affect motility but does cause the type 1 fimbrial promoter to remain in the OFF position. Interestingly, the triose phosphate isomerase mutant, which performs a reversible step in glycolysis and is therefore not specific to the glycolytic pathway, demonstrated extremely limited motility and had a similar reduction in fliA and fliC expression. Importantly, it must be noted that our findings with motility and type 1 fimbrial expression in the glycolytic mutants is not sufficient to explain the urinary tract colonization data, specifically, why the pfkA pfkB double mutant outcompetes wild type. We speculate that the fitness advantage could be partly explained by the diversion of resources in the mutant that would otherwise be consumed by the production of Pfk enzymes, which are not actually needed for growth in the urinary tract.
It is similarly important to note that multiple site-specific recombinases, including HbiF, IpuA, IpuB, IpbA, and FimX, in addition to genetically linked FimB and FimE, have all been reported to affect phase variation of the type 1 fimbrial promoter (40) (41) (42) . These Fim recombinases also mediate phase variation of other invertible elements, including FimX, which inverts hyxS, FimE, FimX, IpuA, and IpuB, which inverts ipuS (43, 44) . When positioned in the on state, invertible element ipuS expresses upaE, which has been shown to result in a motility defect, increased adherence to kidney epithelial cells, and kidney colonization (44) . A second phase variable element hyxS regulates the expression of hyxR, which has been shown to affect resistance to reactive nitrogen species and intracellular macrophage survival (43) . In future studies, it would be interesting to investigate the role and expression of the additional Fim recombinases on type 1 phase variation observed in the glycolytic mutants, as well as examine the phase variation of invertible elements hyxS and ipuS, since they have been found to play a role in pathogenesis. Cofactors H-NS, integration host factor (IHF), and leucineresponsive protein (LRP), in addition to the regulatory alarmone (p)ppGpp, have also been reported to affect type 1 phase variation (45) (46) (47) (48) (49) , and these mechanisms could be affected by disruption in glycolysis.
Previously, Muller et al. have reported that a reduction of intracellular cyclic AMP (cAMP) levels due to the presence of glucose increased E. coli type 1 fimbriation (50). In the cell, adenylate cyclase converts ATP cAMP in response to the amount of glucose being imported into the cell via the PTS system. cAMP receptor protein (CRP) is a cellular target for cAMP, and together this complex acts as a global regulator of gene expression. The negative control by CRP-cAMP on FimB-mediated recombination was found to indirectly require DNA gyrase activity (50) . After static growth in LB medium, we observed over 75% of the PFK mutant population and approximately 60% of the PYK mutant population with the type 1 fim promoter in the off position. In addition, the type 1 fim promoter was oriented in the off position for all of the glycolytic mutants following growth in human urine. These findings are not surprising since LB medium and human urine have no glucose, thus causing an increase in intracellular CRP-cAMP levels, triggering a decrease in type 1 fim expression. It is also possible that disruption in glycolysis under certain conditions could cause a reduction in ATP levels in the cell and that this in turn could affect transcriptional regulation via any number of regulatory pathways that depend on phosphorylation.
Our findings support the hypothesis that glycolysis is dispensable for UPEC fitness during UTI and based on two virulence traits, motility and fimbrial expression, does not appear to affect virulence gene expression. Importantly, our findings suggest that suppression of latent enzymes is an important fitness trait. For example, loss of the primary Pyk leads to a circumstance whereby the latent Pyk creates a fitness defect that can be ameliorated only by removing both Pyk-encoding genes. We also found that the primary Pyk is important to reduce motility, while the latent Pyk II had no effect on this phenotype. We also found that the loss of both Pfk enzymes creates a fitness advantage, which supports the often-touted notion that certain enzymes, proteins, processes, or pathways can be energetically costly under specific circumstances. Presumably, in this case, UPEC has increased fitness in the absence of all Pfk activity and a functional glycolysis pathway during growth on the dilute mixture of amino acids and peptide in the urinary tract microenvironment. Our findings support the notion that UPEC shuttles between the carbon-rich, highly competitive environments of the intestinal tract and the carbohydrate-limited environment of the urinary tract (4, 6), undergoing metabolic flexibility as a means to successfully colonize the disparate host microenvironments.
MATERIALS AND METHODS
Bacteria and growth conditions. E. coli CFT073 was isolated from the blood and urine of a patient with acute pyelonephritis (51) . Lysogeny broth (LB) medium was routinely used to culture bacteria. For in vitro growth experiments, wild-type and mutant strains were cultured in morpholinepropanesulfonic acid (MOPS) defined medium (52) containing either 0.2% (wt/vol) glucose or 0.2% (wt/vol) glycerol as the sole carbon source. Wild-type CFT073 and mutants were also grown in vitro in pooled human urine collected from at least four females and filter sterilized. LB medium and human urine cultures were inoculated 1:100, and defined medium cultures were inoculated 1:50 from overnight LB bacterial cultures and incubated with aeration at 37°C. Growth curves were determined in triplicate, and the OD 600 was recorded every hour.
Construction of glycolysis mutants. E. coli CFT073 deletion mutants (Table 1) were constructed using the lambda red recombinase system (53) . Primers homologous to sequence within the 5= and 3= ends of the gene to be targeted were designed to replace the gene with a nonpolar kanamycin or chloramphenicol resistance cassette amplified from template plasmid pKD4 or pKD3, respectively (53) . E. coli CFT073 mutants were confirmed by PCR amplification using primers flanking the target gene sequence and comparing gene product size to wild-type CFT073 PCR product size. To decipher negligible product sizes PCR mixtures were digested with a restriction enzyme (New England Biolabs). The oligonucleotides used to construct the pfkA, pfkB, pfkA pfkB, pykA, pykF, and pykA pykF mutants and to confirm the mutations are listed in Table S1 in the supplemental material.
Complementation of mutants. To perform in vitro complementation experiments, constructs were designed by individually PCR amplifying pfkA and pykF from wild-type CFT073 genomic DNA using Easy-A high-fidelity polymerase (Agilent), digestion with SphI and NotI restriction enzymes (New England Biolabs), and cloning into pGEN-MCS (54) . The oligonucleotides used for complementation vector construction for the pfkA and pykF mutant strains are listed on Table S1 . The sequence of pGEN-pfkA and pGEN-pykF was confirmed by sequence analysis prior to transformation into the single pfkA and double pfkA pfkB mutants and the single pykF and double pykA pykF mutants, respectively.
Experimental UTI. The fitness contribution of each CFT073 glycolysis mutant during cochallenge competition was assessed in the CBA mouse model of ascending UTI (55, 56) . Female CBA/J mice (6 to 8 weeks old; 20 to 22 g; Jackson Laboratories) were anesthetized with ketamine-xylazine and transurethrally inoculated with a 50 l of bacterial suspension of 2 ϫ 10 8 CFU per mouse using a sterile Infected mice were euthanized 48 h postinfection; the bladders and kidneys were aseptically removed, weighed, and homogenized (OMNI International) in 3 ml of PBS, and appropriate dilutions were spiral plated on LB agar with or without antibiotic to determine the output CFU/gram of tissue. Viable counts were enumerated using QCount software (Spiral Biotech) and CFU from antibiotic-containing medium (mutant CFU) were subtracted from the total CFU from plates lacking antibiotic to determine the number of wild-type bacteria. For cochallenge experiments, competitive indices (CI) were calculated by dividing the ratio of the CFU of mutant to wild type recovered from each mouse after infection by the ratio of the CFU of mutant to the CFU of wild type present in the input. CI data were log transformed and analyzed by using a Wilcoxon signed-rank test to determine statistically significant differences in colonization (P Ͻ 0.05). A CI of Ͼ1 indicates that the mutant outcompetes the wild-type strain, and a CI of Ͻ1 indicates that the mutant is outcompeted by the wild-type strain. Motility assays. The swimming motility of wild-type E. coli CFT073 and glycolysis mutants was observed on soft agar plates (10 g/liter tryptone, 5 g/liter NaCl, and 2.5 g/liter Bacto agar). Overnight bacterial cultures grown shaking at 37°C were normalized to an OD 600 of 1.0 in tryptone broth (10 g/liter) and, using a sterile inoculating needle, stabbed into the center of the motility agar, followed by incubation at 30°C for 16 h. The diameter of swimming was measured for each strain. Experiments were performed in duplicate and repeated for a total of three biological replicates. The statistical significance was determined by one-way analysis of variance (ANOVA) with Dunnett's multiple-comparison test.
Invertible element PCR assay. Pyelonephritis isolate CFT073, previously constructed type 1 fimbria mutants with the promoter situated in the on orientation (fim L-ON) or situated in the off orientation (fim L-OFF) within the invertible element (IE) (57) , and all glycolysis mutants were incubated statically in LB medium at 37°C for 18 h or human urine at 37°C for 48 h. LB medium cultures were standardized to an OD 600 of 0.5. Human urine cultures were spun down and resuspended in water. The IE PCR assay was conducted as described previously (58) . In brief, oligonucleotides (see Table S1 in the supplemental material) were used to amplify the 601-bp invertible element. PCR products were subsequently digested with SnaBI and electrophoresed on a 3% agarose-1ϫ Tris-acetate-EDTA buffer (TAE) gel to determine the orientation of the fim promoter within the IE. Digestion of the IE PCR product with the fim promoter positioned in the on orientation results in 403-and 198-bp bands, while digestion of the IE PCR product with the fim promoter positioned in the off orientation results in 440-and 161-bp bands. To determine the proportion of IE DNA with the fim promoter situated in the on and off orientations, the pixel intensities of the bands on the gel image calculated by Image Lab 6.0 Software (Bio-Rad) were examined. In brief, pixel intensities of both PCR product bands of the fim promoter positioned in the on or off orientation were added together to find the total bacterial population with the fim promoter positioned in the on or off orientation, respectively. Each total bacterial population value (total fim on or total fim off) was then divided by the total sum of pixel intensity (total fim on and total fim off) to calculate the percent bacterial population with the IE containing the fim promoter positioned in the on or off orientation.
qPCR. Overnight bacterial cultures of wild-type CFT073, glycolysis mutants, and the type 1 fimbria mutants fim L-ON and fim L-OFF (57) were back diluted (1:100) and grown shaking in LB at 37°C for approximately 2 to 3 h to an OD 600 of 0.5 to 0.6. For RNA stabilization, a 2:1 (vol/vol) ratio of RNA protect (Qiagen) was added to 250 l of bacterial sample and spun down (Thermo Scientific Legend Micro 21, room temperature, 5 min, 9,600 ϫ g). Subsequent RNA isolation was performed with an RNeasy minikit (Qiagen), followed by DNase treatment of RNA with a Turbo DNA-free kit (Invitrogen). PCR with primers to amplify the glyceraldehyde-3-phosphate dehydrogenase housekeeping gene (gapA) was performed to check for contaminating DNA. cDNA synthesis was performed on DNA-free RNA samples with an iScript kit (Bio-Rad). Then, 5 ng of total cDNA was added to each reaction, and qPCR was performed with SyberGreen PowerUp reagent (Invitrogen) with primers to amplify the following genes: fliA, RNA polymerase sigma factor for flagellar operon; fliC, flagellin assembly; fimA, type 1 fimbrial protein; and papA and papA2, major pilin subunit A. gapA expression was used as the internal control to calculate relative expression values of experimental genes. The comparative threshold cycle (C T ) method was used to determine the relative fold change compared to wild-type CFT073. Oligonucleotides for the qPCR experiments are listed in Table S1 .
Ethics statement. All animal experiments were performed in accordance with the protocol 08999-3 approved by the University Committee on Use and Care of Animals at the University of Michigan. This protocol is in complete compliance with the guidelines for humane use and care of laboratory animals mandated by the National Institutes of Health.
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